As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
A new study shows that the risk of developing dementia anytime after age 55 among Americans is 42%, more than double the risk reported by older studies.